Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review

Contraception

Volumn 81, Issue 3, 2010, Pages 185-196

  Zahradnik, Hans Peter ^a   Hanjalic Beck, Aida ^a   Groth, Klaus ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Dysmenorrhea; Hormonal contraceptives; Nonsteroidal anti inflammatory drugs; Pain relief

Indexed keywords

ACECLOFENAC; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; CONTRACEPTIVE AGENT; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DICLOFENAC POTASSIUM; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FENNEL EXTRACT; GUAVA EXTRACT; IBUPROFEN; LUMIRACOXIB; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; NORGESTREL; PARACETAMOL; PLANT EXTRACT; ROFECOXIB; SUPROFEN; UNCLASSIFIED DRUG; VALDECOXIB;

ANALGESIA; BLEEDING; BOTHERSOMENESS; BREAST TENDERNESS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSMENORRHEA; EDEMA; EPIGASTRIC PAIN; FATIGUE; FEMALE; FENNEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HORMONAL CONTRACEPTION; HUMAN; INCIDENCE; INFORMATION RETRIEVAL; IRRITABILITY; KIDNEY FAILURE; LIVER FAILURE; LIVER TUMOR; MEDLINE; METHODOLOGY; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; PUBLIC HEALTH PROBLEM; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOCIOECONOMICS; SYSTEMATIC REVIEW; THROMBOSIS; TINNITUS; ULCER; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VAGINAL DISCOMFORT; VISUAL DISORDER;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONTRACEPTIVES, ORAL, HORMONAL; DYSMENORRHEA; FEMALE; HUMANS;

EID: 76049107073     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.09.014     Document Type: Review

References (101)

1. Cameron I.T. Menstrual disorders. In: Edmonds D.K. (Ed). Dewhurst's textbook of obstetrics and gynaecology for postgraduates. 6th ed (1999), Blackwell Science, London 410-419
2. National Library for Health. Dysmenorrhoea. [cited 2008 21 October]; Available from:. http://www.cks.library.nhs.uk/dysmenorrhoea
3. Rees M.C.P. Menstrual problems. In: Waller D., and McPherson A. (Eds). Women's health. 5th ed (2003), Oxford University Press, Oxford 1-45
4. Dawood M.Y. Dysmenorrhea. Clin Obstet Gynecol 33 (1990) 168-178
5. Lumsden M., and Norman J. Menstruation and menstrual abnormality. In: Shaw R.W., Soutter W.P., and Stanton S.L. (Eds). Gynaecology. 2nd ed (1997), Edinburgh, Churchill Livingston 421-439
6. Nasir L., and Bope E.T. Management of pelvic pain from dysmenorrhea or endometriosis. J Am Board Fam Pract 17 Suppl (2004) S43-S47
7. Hillen T.I., Grbavac S.L., Johnston P.J., Straton J.A., and Keogh J.M. Primary dysmenorrhea in young Western Australian women: prevalence, impact, and knowledge of treatment. J Adolesc Health 25 (1999) 40-45
8. Smith R.P. Cyclic pelvic pain and dysmenorrhea. Obstet Gynecol Clin North Am 20 (1993) 753-764
9. Andersch B., and Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 144 (1982) 655-660
10. Banikarim C., Chacko M.R., and Kelder S.H. Prevalence and impact of dysmenorrhea on Hispanic female adolescents. Arch Pediatr Adolesc Med 154 (2000) 1226-1229
11. Campbell M.A., and McGrath P.J. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 151 (1997) 905-913
12. Harlow S.D., and Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 103 (1996) 1134-1142
13. Klein J.R., and Litt I.F. Epidemiology of adolescent dysmenorrhea. Pediatrics 68 (1981) 661-664
14. Robinson J.C., Plichta S., Weisman C.S., Nathanson C.A., and Ensminger M. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol 166 (1992) 578-583
15. Svanberg L., and Ulmsten U. The incidence of primary dysmenorrhea in teenagers. Arch Gynecol 230 (1981) 173-177
16. Wilson C.A., and Keye Jr. W.R. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. J Adolesc Health Care 10 (1989) 317-322
17. Burnett M.A., Antao V., Black A., et al. Prevalence of primary dysmenorrhea in Canada. J Obstet Gynaecol Can 27 (2005) 765-770
18. Ohde S., Tokuda Y., Takahashi O., Yanai H., Hinohara S., and Fukui T. Dysmenorrhea among Japanese women. Int J Gynaecol Obstet 100 (2008) 13-17
19. Sundell G., Milsom I., and Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 97 (1990) 588-594
20. 2 alpha. Br J Obstet Gynaecol 90 (1983) 1135-1140
21. Lundstrom V., and Green K. Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 130 (1978) 640-646
22. 2 in normal and dysmenorrheic women and their temporal relationship to dysmenorrhea. Prostaglandins 29 (1985) 273-290
23. Stromberg P., Akerlund M., Forsling M.L., Granstrom E., and Kindahl H. Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea. Acta Obstet Gynecol Scand 63 (1984) 533-538
24. Ylikorkala O., and Dawood M.Y. New concepts in dysmenorrhea. Am J Obstet Gynecol 130 (1978) 833-847
25. Czekanowski R., Mosler K.H., and Schwalm H. Influence of prostaglandin F2-alpha on the contractility of the nonpregnant human uterus in vitro. Z Geburtshilfe Perinatol 177 (1973) 202-209
26. Zahradnik H.P., Steiner H., Hillemanns H.G., Breckwoldt M., and Ardelt W. Prostaglandin F2alpha- and 15-methyl-prostaglandin F2alpha-application for the treatment of severe uterine bleedings (author's transl). Geburtshilfe Frauenheilkd 37 (1977) 493-495
27. Zahradnik H.P., Stengele E., Kraut E., Scharpf G., and Breckwoldt M. New aspects in the pathogenesis and therapy of dysmenorrhea: prostoglandin F2 alpha level in the menstrual blood. Dtsch Med Wochenschr 103 (1978) 1270-1273
28. Zahradnik H.P., Stengele E., Kraut E., Scharpf G., and Breckwoldt M. The effect of progesterone uterine therapeutic system on dysmenorrhoea: prostaglandin F2alpha levels in menstrual blood (author's transl). Dtsch Med Wochenschr 103 (1978) 1270-1273
29. Miller N.F. Additional light on dysmenorrhea problem. JAMA 95 (1930) 1796-1803
30. Zahradnik H.P., Wetzka B., and Schuth W. Zyklusabhängige Befindlichkeitsstörungen der Frau. Gynäkologe 33 (2000) 225-238
31. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56 (2002) 365-379
32. Frisch R.E., and Revelle R. Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science 169 (1970) 397-399
33. Bau A.M., Ernert A., Schenk L., et al. Is there a further acceleration in the age at onset of menarche? A cross-sectional study in 1840 school children focusing on age and bodyweight at the onset of menarche. Eur J Endocrinol 160 (2009) 107-113
34. Danubio M.E., De Simone M., Vecchi F., Amicone E., Altobelli E., and Gruppioni G. Age at menarche and age of onset of pubertal characteristics in 6-14-year-old girls from the Province of L'Aquila (Abruzzo, Italy). Am J Hum Biol 16 (2004) 470-478
35. Rosenfield R.L., Lipton R.B., and Drum M.L. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 123 (2009) 84-88
36. Wattigney W.A., Srinivasan S.R., Chen W., Greenlund K.J., and Berenson G.S. Secular trend of earlier onset of menarche with increasing obesity in black and white girls: the Bogalusa Heart Study. Ethn Dis 9 (1999) 181-189
37. Sinha A., and Kling S. A review of adolescent obesity: prevalence, etiology, and treatment. Obes Surg 19 (2009) 113-120
38. Moos R.H. The development of a menstrual distress questionnaire. Psychosom Med 30 (1968) 853-867
39. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1 (1975) 277-299
40. Chan W.Y. Prostaglandins and nonsteroidal antiinflammatory drugs in dysmenorrhea. Annu Rev Pharmacol Toxicol 23 (1983) 131-149
41. Chan W.Y., Fuchs F., and Powell A.M. Effects of naproxen sodium on menstrual prostaglandins and primary dysmenorrhea. Obstet Gynecol 61 (1983) 285-291
42. Dawood M.Y. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. Drugs 22 (1981) 42-56
43. Dawood M.Y. Ibuprofen and dysmenorrhea. Am J Med 77 (1984) 87-94
44. Dawood M.Y. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med 84 (1988) 23-29
45. Guttadauria M. The clinical pharmacology of piroxicam. Acta Obstet Gynecol Scand Suppl 138 (1986) 11-13
46. Kauppila A., Makila U.M., Makarainen L., Puolakka J., and Seppala A. Tiaprofenic acid in the treatment of primary dysmenorrhoea. Eur J Obstet Gynecol Reprod Biol 22 (1986) 359-363
47. Milsom I., Andersch B., and Sundell G. The effect of flurbiprofen and naproxen sodium on intra-uterine pressure and menstrual pain in patients with primary dysmenorrhea. Acta Obstet Gynecol Scand 67 (1988) 711-716
48. Owen P.R. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol 148 (1984) 96-103
49. Pasquale S.A., Rathauser R., and Dolese H.M. A double-blind, placebo-controlled study comparing three single-dose regimens of piroxicam with ibuprofen in patients with primary dysmenorrhea. Am J Med 84 (1988) 30-34
50. Pulkkinen M.O. Alterations in intrauterine pressure, menstrual fluid prostaglandin F levels, and pain in dysmenorrheic women treated with nimesulide. J Clin Pharmacol 27 (1987) 65-69
51. Nigam S., Benedetto C., Zonca M., Leo-Rossberg I., Lubbert H., and Hammerstein J. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 4 (1991) 137-141
52. Buhimschi I., Yallampalli C., Dong Y.L., and Garfield R.E. Involvement of a nitric oxide-cyclic guanosine monophosphate pathway in control of human uterine contractility during pregnancy. Am J Obstet Gynecol 172 (1995) 1577-1584
53. Izumi H., Yallampalli C., and Garfield R.E. Gestational changes in l-arginine-induced relaxation of pregnant rat and human myometrial smooth muscle. Am J Obstet Gynecol 169 (1993) 1327-1337
54. The Transdermal Nitroglycerine/Dysmenorrhoea Study Group. Transdermal nitroglycerine in the management of pain associated with primary dysmenorrhoea: a multinational pilot study. J Int Med Res 25 (1997) 41-44
55. Moya R.A., Moisa C.F., Morales F., Wynter H., Ali A., and Narancio E. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet 69 (2000) 113-118
56. Pittrof R., Lees C., Thompson C., Pickles A., Martin J.F., and Campbell S. Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea. BMJ 312 (1996) 884
57. Pullon S., Reinken J., and Sparrow M. Prevalence of dysmenorrhoea in Wellington women. N Z Med J 101 (1988) 52-54
58. Backon J. Negative correlation of cigarette smoking and dysmenorrhea: reduced prostaglandin synthesis due to beta-endorphin, nicotine, or acrolein antagonism. Med Hypotheses 28 (1989) 213-214
59. Li N., Liu H., Chen C., et al. CYP1A1 gene polymorphisms in modifying the association between passive smoking and primary dysmenorrhea. Ann Epidemiol 17 (2007) 882-888
60. Wu D., Wang X., Chen D., et al. Metabolic gene polymorphisms and risk of dysmenorrhea. Epidemiology 11 (2000) 648-653
61. Liu H., Yang F., Li Z., et al. Passive smoking, Cyp1A1 gene polymorphism and dysmenorrhea. Reprod Toxicol 24 (2007) 114-119
62. Montero P., Bernis C., Fernandez V., and Castro S. Influence of body mass index and slimming habits on menstrual pain and cycle irregularity. J Biosoc Sci 28 (1996) 315-323
63. Alonso C., and Coe C.L. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol 20 (2001) 411-416
64. Wang L., Wang X., Wang W., et al. Stress and dysmenorrhoea: a population based prospective study. Occup Environ Med 61 (2004) 1021-1026
65. Coco A.S. Primary dysmenorrhea. Am Fam Physician 60 (1999) 489-496
66. Davis A.R., and Westhoff C.L. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol 14 (2001) 3-8
67. Giamberardino M.A., Berkley K.J., Iezzi S., de Bigontina P., and Vecchiet L. Pain threshold variations in somatic wall tissues as a function of menstrual cycle, segmental site and tissue depth in non-dysmenorrheic women, dysmenorrheic women and men. Pain 71 (1997) 187-197
68. Baker F.C., Driver H.S., Rogers G.G., Paiker J., and Mitchell D. High nocturnal body temperatures and disturbed sleep in women with primary dysmenorrhea. Am J Physiol 277 (1999) E1013-1021
69. Baranowski A.P., Abrams P., and Fall M. Urogenital pain in clinical practice (2007), Informa Healthcare USA, Inc., New York
70. In: Gowans G. (Ed). Monthly Index of Medical Specialities (2008), Wyndham Heron Ltd, Maldon, Essex
71. Marjoribanks J., Proctor M.L., and Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev (2003) CD001751
72. Oberholzer B., Hoigne R., Hartmann K., et al. Incidence of drug side effects by symptoms and syndromes. From the experiences of the Comprehensive Hospital Drug Monitoring and the Swiss Drug Side Effect Center. As an example: allergic and pseudo-allergic reactions with mild analgesics and NSAID. Ther Umsch 50 (1993) 13-19
73. Daniels S., Gitton X., Zhou W., Stricker K., and Barton S. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials. J Womens Health (Larchmt) 17 (2008) 423-437
74. Gallo M.F., Nanda K., Grimes D.A., Lopez L.M., and Schulz K.F. 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev (2008) CD003989
75. Zahradnik H.P., Goldberg J., and Andreas J.O. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 57 (1998) 103-109
76. O'Connell K., Davis A.R., and Kerns J. Oral contraceptives: side effects and depression in adolescent girls. Contraception 75 (2007) 299-304
77. Proctor M.L., Hing W., Johnson T.C., and Murphy P.A. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev (2001) CD002119
78. Proctor M.L., and Murphy P.A. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev (2001) CD002124
79. Proctor M.L., Smith C.A., Farquhar C.M., and Stones R.W. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev (2002) CD002123
80. Davis A.R., Westhoff C., O'Connell K., and Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 106 (2005) 97-104
81. Winkler U.H., Ferguson H., and Mulders J.A. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 69 (2004) 469-476
82. Ahrendt H.J., Karck U., Pichl T., Mueller T., and Ernst U. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care 12 (2007) 354-361
83. Harel Z., Riggs S., Vaz R., Flanagan P., Dunn K., and Harel D. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol 18 (2005) 85-90
84. Kido A., Togashi K., Kataoka M., et al. The effect of oral contraceptives on uterine contractility and menstrual pain: an assessment with cine MR imaging. Hum Reprod 22 (2007) 2066-2071
85. Matsumoto Y., Yamabe S., Ideta K., and Kawabata M. Impact of use of combined oral contraceptive pill on the quality of life of Japanese women. J Obstet Gynaecol Res 33 (2007) 529-535
86. Sabatini R., Orsini G., Cagiano R., and Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 76 (2007) 342-347
87. Schramm G., and Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception 76 (2007) 84-90
88. Bitner M., Kattenhorn J., Hatfield C., Gao J., and Kellstein D. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract 58 (2004) 340-345
89. Chantler I., Mitchell D., and Fuller A. The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic pain. Clin J Pain 24 (2008) 39-44
90. Daniels S.E., Torri S., and Desjardins P.J. Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen. J Gen Intern Med 20 (2005) 62-67
91. 2 by suprofen in women with primary dysmenorrhea. Prostaglandins Other Lipid Mediat 83 (2007) 146-153
92. Dawood M.Y., and Khan-Dawood F.S. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. Am J Obstet Gynecol 196 (2007) 35.e1-35.e5
93. de Mello N.R., Baracat E.C., Tomaz G., et al. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 83 (2004) 667-673
94. Doubova S.V., Morales H.R., Hernandez S.F., et al. Effect of a Psidii guajavae folium extract in the treatment of primary dysmenorrhea: a randomized clinical trial. J Ethnopharmacol 110 (2007) 305-310
95. Letzel H., Megard Y., Lamarca R., Raber A., and Fortea J. The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea. Eur J Obstet Gynecol Reprod Biol 129 (2006) 162-168
96. Modaress Nejad V., and Asadipour M. Comparison of the effectiveness of fennel and mefenamic acid on pain intensity in dysmenorrhoea. East Mediterr Health J 12 (2006) 423-427
97. Edwards J.E., Moore R.A., and McQuay H.J. Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data. BMC Womens Health 4 (2004) 5
98. Proctor M.L., Roberts H., and Farquhar C.M. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev (2001) CD002120
99. Zhang W.Y., and Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 105 (1998) 780-789
100. French L. Dysmenorrhea. Am Fam Physician 71 (2005) 285-291
101. Graham D.Y., Opekun A.R., Willingham F.F., and Qureshi W.A. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 3 (2005) 55-59